| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology and Epileptology (Drs. de Haan, Engelsman, and Augustijn, M. Dévilé-Notschaele) and Laboratory of Clinical Chemistry and Clinical Pharmacology (Dr. Edelbroek, J. Segers), Epilepsy Institute of the Netherlands SEIN, Heemstede, The Netherlands; and DBG-Department of Medical Genetics (Dr. Lindhout), University Medical Center, Utrecht, The Netherlands.
Address correspondence and reprint requests to Dr. G-J. de Haan, Neurologist, SEIN, P.O. Box 21, 2100 AA Heemstede, The Netherlands; e-mail: gjdhaan{at}sein.nl
The authors describe 12 pregnancies in women with epilepsy using lamotrigine (LTG) monotherapy. A seizure increase in nine pregnancies was probably related to a gradual decline of LTG level-to-dose ratio to 40% of baseline. After delivery, LTG kinetics returned swiftly to baseline, causing toxic side effects in some women. Frequent LTG level monitoring and appropriate dose adjustments are advised in the period before and during pregnancy and after delivery, especially in women on LTG monotherapy.
Received January 5, 2004. Accepted in final form March 25, 2004.
G-J.H., P.E., M.E., and P.A. have contributed in the past to registration and postmarketing studies sponsored by GSK. D.L. is leader of the Benelux/Netherlands branch of the EURAP study, which is cosponsored by GSK. This report is unrelated to any of these studies and was not financially supported.
Related Article
Neurology 2004 63: 408-409.
This article has been cited by other articles:
|
|
 |
|
  P. B. Pennell, L. Peng, D. J. Newport, J. C. Ritchie, A. Koganti, D. K. Holley, M. Newman, and Z. N. Stowe Lamotrigine in pregnancy: Clearance, therapeutic drug monitoring, and seizure frequency Neurology, May 27, 2008; 70(22_Part_2): 2130 - 2136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Montouris Importance of monotherapy in women across the reproductive cycle Neurology, December 11, 2007; 69(24_suppl_3): S10 - S16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Tomson and V. Hiilesmaa Epilepsy in pregnancy BMJ, October 13, 2007; 335(7623): 769 - 773. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Baumann Salivary Monitoring of Antiepileptic Drugs Journal of Pharmacy Practice, April 1, 2007; 20(2): 147 - 157. [Abstract] [PDF]
|
|
|
|
|
|
R. Kalviainen and T. Tomson Optimizing treatment of epilepsy during pregnancy Neurology, December 26, 2006; 67(12_suppl_4): S59 - S63. [Abstract] [Full Text]
|
|
|
|
|
|
T. Tomson, G. Luef, A. Sabers, S. Pittschieler, and I. Ohman Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology, October 10, 2006; 67(7): 1297 - 1299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Williams, C Lawthom, F D Dunstan, T P Dawson, M P Kerr, J F Wilson, and P E M Smith Variability of antiepileptic medication taking behaviour in sudden unexplained death in epilepsy: hair analysis at autopsy J. Neurol. Neurosurg. Psychiatry, April 1, 2006; 77(4): 481 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
The EURAP Study Group Seizure control and treatment in pregnancy: Observations from the EURAP Epilepsy Pregnancy Registry Neurology, February 14, 2006; 66(3): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M D O'Brien and S K Gilmour-White Management of epilepsy in women Postgrad. Med. J., May 1, 2005; 81(955): 278 - 285. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Kaplan Reproductive health effects and teratogenicity of antiepileptic drugs Neurology, November 23, 2004; 63(10_suppl_4): S13 - S23. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
